EUVIMEDEUVIMED entdecken
Crossref

Discovery of Selective and Orally Available Galectin-1 Inhibitors

Fredrik R Zetterberg iD, Carl Diehl, Maria Håkansson, Barbro Kahl-Knutson, Hakon Leffler iD, Ulf J Nilsson iD, Kristoffer Peterson, James A Roper iD, Robert J Slack

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Fredrik R Zetterberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, SE-413 46 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Galectin 1, Galectin 3, Hydrocarbons, Fluorinated, Triazoles. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Galecto ApS, Galecto Biotech AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new series of orally available α-d-galactopyranosides with high affinity and specificity toward galectin-1 have been discovered. High affinity and specificity were achieved by changing six-membered aryl-triazolyl substituents in a series of recently published galectin-3-selective α-d-thiogalactosides (e.g., GB1107 Kd galectin-1/3 3.7/0.037 μM) for five-membered heterocycles such as thiazoles. The in vitro pharmacokinetic properties were optimized, resulting in several galectin-1 inhibitors with favorable properties. One compound, GB1490 (Kd galectin-1/3 0.4/2.7 μM), was selected for further characterization toward a panel of galectins showing a selectivity of 6- to 320-fold dependent on galectin. The X-ray structure of GB1490 bound to galectin-1 reveals the compound bound in a single conformation in the carbohydrate binding site. GB1490 was shown to reverse galectin-1-induced apoptosis of Jurkat cells at low μM concentrations. No cell cytotoxicity was observed for GB1490 up to 90 μM in the A549 cells. In pharmacokinetic studies in mice, GB1490 showed high oral bioavailability (F% > 99%).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 1Galectin 3Hydrocarbons, FluorinatedTriazolesAnimalsHumansMiceBinding SitesCarbohydratesJurkat Cells

Substanzen

CarbohydratesGalectin 1Galectin 3(2R,3R,4S,5R,6R)-2-(3,4-dichlorophenyl)sulfanyl-6-(hydroxymethyl)-4-(4-(3,4,5-trifluorophenyl)triazol-1-yl)oxane-3,5-di…Hydrocarbons, FluorinatedTriazoles

Autor:innen und Institutionen

  • Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, SE-413 46 Gothenburg, Sweden.
  • SARomics Biostructures AB, Medicon Village, SE-223 81 Lund, Sweden.
  • Department of Laboratory Medicine, Lund University, Box 124, SE-221 00, Lund, Sweden.
  • Department of Chemistry, Lund University, Box 124, SE-221 00 Lund, Sweden.
  • Stevenage Bioscience Catalyst, Galecto Biotech ApS, Stevenage, Hertfordshire SG1 2FX U.K.

ORCID-Profile: Fredrik R Zetterberg, Hakon Leffler, Ulf J Nilsson, James A Roper

Förderung

  • Galecto ApS
  • Galecto Biotech AB

Zitieren

APA

Zetterberg, F. R., Diehl, C., Håkansson, M., Kahl-Knutson, B., Leffler, H., Nilsson, U. J., Peterson, K., Roper, J. A., & Slack, R. J. (2023). Discovery of Selective and Orally Available Galectin-1 Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01787

Vancouver

Zetterberg FR, Diehl C, Håkansson M, Kahl-Knutson B, Leffler H, Nilsson UJ, et al. Discovery of Selective and Orally Available Galectin-1 Inhibitors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01787

BibTeX
@article{Zetterberg2023,
  author = {Zetterberg, Fredrik R and Diehl, Carl and Håkansson, Maria and Kahl-Knutson, Barbro and Leffler, Hakon and Nilsson, Ulf J and Peterson, Kristoffer and Roper, James A and Slack, Robert J},
  title = {Discovery of Selective and Orally Available Galectin-1 Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01787}
}
Kostenlos starten →